AURELIO-04: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SOT101 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS

被引：1
|
作者：
Champiat, Stephane [1 ]
Marabelle, Aurelien [1 ]
Davar, Diwakar [2 ]
Grell, Peter [3 ]
Ouali, Kaissa [1 ]
Patrikidou, Anna [1 ]
Schoenenberger, Andreu [4 ]
Jelinkova, Lenka Palova [4 ]
Adkins, Irena [4 ]
Tillmanns, Sascha [5 ]
Kiemle-Kallee, Joachim [5 ]
Sachse, Richard [5 ]
Garralda, Elena [6 ]
机构：
[1] Gustave Roussy, Villejuif, France
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Masaryk Mem Canc Inst, Brno, Czech Republic
[4] SOTIO Biotech AS, Prague, Czech Republic
[5] SOTIO Biotech AG, Basel, Switzerland
[6] Vall dHebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0716
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
716
引用
收藏
页码：A749 / A749
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
    Yap, Timothy A.
    Nakagawa, Kazuhiko
    Fujimoto, Nobukazu
    Kuribayashi, Kozo
    Guren, Tormod Kyrre
    Calabro, Luana
    Shapira-Frommer, Ronnie
    Gao, Bo
    Kao, Steven
    Matos, Ignacio
    Planchard, David
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Kindler, Hedy L.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
  • [2] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [3] A multicenter, open-label, single-arm, phase IV study evaluating the safety of biosimilar bevacizumab in patients with solid tumors
    Narayanan, P.
    Upveja, K. H.
    Deodhar, S.
    Kapur, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1613 - S1613
  • [4] A MULTICENTER OPEN-LABEL PHASE I/LB STUDY OF SO-C101 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS
    Marabelle, Aurelien
    Champiat, Stephane
    Garralda, Elena
    Hernando, Alberto
    Janku, Filip
    Raina, Anjali
    Sachse, Richard
    Bechard, David
    Krasnopolskaya, Inna
    Ferrara, Stefano
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A483 - A483
  • [5] Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor ßγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
    Garralda, Elena
    Naing, Aung
    Galvao, Vladimir
    LoRusso, Patricia
    Grell, Peter
    Cassier, Philippe Alexandre
    Gomez-Roca, Carlos A.
    Korakis, Iphigenie
    Bechard, David
    Jelinkova, Lenka Palova
    Adkins, Irena
    Tillmanns, Sascha
    Kiemle-Kallee, Joachim
    Marabelle, Aurelien
    Champiat, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
    Si, Lu
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Wei, Xiaoting
    Sun, Peng
    Jia, Zhongwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [8] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [9] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [10] Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
    Park, Joon Oh
    Feng, Yin-Hsun
    Su, Wu-Chou
    Oh, Do-Youn
    Keam, Bhumsuk
    Shen, Lin
    Kim, Sang-We
    Liu, Xiufeng
    Liao, Huimin
    Qing, Min
    Zhang, Chong
    Qian, Jiaqi
    Tang, Xiaodan
    Li, Peng
    Triantos, Spyros
    Sweiti, Hussein
    BMC CANCER, 2024, 24 (01)
12345